Roman Perez-Soler
Division of Medical Oncology
Department of Oncology
Montefiore Medical Center
Albert Einstein College of Medicine
USA
Name/email consistency: high
- Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Pérez-Soler, R. Oncogene (2009)
- Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer. Perez-Soler, R. Clin. Cancer Res. (2007)
- Clinical research of EGFR inhibitors and related dermatologic toxicities. Perez-Soler, R., Van Cutsem, E. Oncology (Williston Park, N.Y.) (2007)
- Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Perez-Soler, R. Clin. Lung. Cancer (2006)
- HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Pérez-Soler, R., Delord, J.P., Halpern, A., Kelly, K., Krueger, J., Sureda, B.M., von Pawel, J., Temel, J., Siena, S., Soulières, D., Saltz, L., Leyden, J. Oncologist (2005)
- Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. Peréz-Soler, R., Saltz, L. J. Clin. Oncol. (2005)
- HER1/EGFR targeting: refining the strategy. Pérez-Soler, R. Oncologist (2004)
- Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. Pérez-Soler, R., Chachoua, A., Hammond, L.A., Rowinsky, E.K., Huberman, M., Karp, D., Rigas, J., Clark, G.M., Santabárbara, P., Bonomi, P. J. Clin. Oncol. (2004)
- Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Perez-Soler, R. Clin. Lung. Cancer (2004)
- Tyrosine kinase inhibitors: a clinical perspective. Goel, S., Mani, S., Perez-Soler, R. Curr. Oncol. Rep (2002)